SOURCE: IDenta Corp.

May 21, 2007 10:15 ET

International Drug & Explosives Detection Company IDenta Finalizes Agreement With Jant Pharmacal - Accutest® - IDenta Co-Branded Drug Detection Products Being Shipped

HEATHROW, FL -- (MARKET WIRE) -- May 21, 2007 -- IDenta Corp. (PINKSHEETS: IDTA) announced today that it has signed a comprehensive co-branding and marketing agreement with Jant Pharmacal Corporation. The agreement comes seven months after IDenta agreed to co-brand its line of drug detection products with Jant's own Accutest® label. Details of the comprehensive agreement were finalized during the recent U.S. marketing mission when officials from IDenta spent six days in the Los Angeles marketplace including significant time at the Jant Pharmacal Corporation headquarters in Encino, California. www.accutest.net

"This is a landmark agreement for IDenta which puts our product in the hands of an industry leader," declared Yaacov Shoham, IDTA CEO. "After our initial agreement to develop the new co-branded drug detection products, Jant and IDenta have closely reviewed every aspect of our new offering including pricing, training, insurance, liability issues, packaging, disclaimers, shipping, and every other procedure related to this program. We have agreed that the initial focus of the relationship will be to sell drug detection products to law enforcement channels. The co-branding of our explosive detectors will be reviewed at a later time."

The new agreement with Jant also allows all existing IDenta U.S. business relationships to remain intact, and is expected to actually strengthen these endeavors. Detailed marketing plans, new training materials and new product packaging have been developed in the past seven months. In particular relation to the new IDenta venture, Jant has established relationships with legal and law enforcement agencies at the local, state and federal levels through an extensive, experienced distributor network that covers all fifty states. Additionally Jant has participated in three major shows law enforcement shows to gauge interest in our new venture.

Shoham concluded, "I'm happy to report that hundreds of leads have been generated from their commitment to our mutual success. Both companies believe that it is possible that in the next two years, the Accutest - IDenta Drug Detectors could well be seen as the preferred drug detection products for use by legal and law enforcement agencies across the U.S."

The new product packaging carries a much stronger competitive message showing the Accutest® - IDenta product advantages. The packaging reads:

--  No plastic bags
--  No Loose Ampules or Tubes
--  No Measuring or Mixing of Reagents
--  No Mess
    
See: http://www.accutest.net/products/identa.php

An initial of order of 10,000 units are being shipped to Jant the new packaging design.

ABOUT JANT PHARMACAL CORPORATION

Jant Pharmacal Corporation is recognized as an industry leader in the diagnostics industry. Established in 1986, Jant provides a comprehensive line of rapid immuno-diagnostic test products for legal, law enforcement, clinical, consumer, and workplace applications including saliva and urine drug tests, alcohol tests, tobacco tests and pregnancy & fertility tests.

Products are marketed under Jant's proprietary labels, including Accutest® and Accustrip®, through national and international distributors, as well as through client private labels.

For more information about the Accutest® - IDenta product line please contact:

Mr. Eyal Golan, COO
JANT PHARMACAL CORPORATION
16255 Ventura Blvd. #505
Encino, CA 91436
Toll Free: 800-676-5565
www.accutest.net
ABOUT IDENTA

Since 2003, IDenta Corporation has become recognized as a world-wide leader in the development of proprietary on-site drug detection kits and most recently explosive detection kits. IDenta develops, manufactures and distributes products for the both professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world. Information concerning IDenta's entire product line may be found at www.IDenta.biz.

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

Contact Information

  • Contact:

    For Investor Relations, lobbying interests or information concerning
    IDenta's products internationally contact:

    Yaacov Shoham
    IDenta Corp.
    CEO
    Tel: +972-52-6554487
    +972-8-9716874
    Fax: +972-8-9716875
    fpi@drugsdetector.com

    For Investor Relations in the United States contact:
    Randy Jacobs
    US Corporate Spokesman
    IDentaNews@sitcomllc.com
    1-800-316-9437

    For more information about the Accutest® - IDenta product line please
    contact:
    Mr. Eyal Golan
    COO
    JANT PHARMACAL CORPORATION
    16255 Ventura Blvd. #505
    Encino, CA 91436
    Toll Free: 800-676-5565
    www.accutest.net